Literature DB >> 21190850

Structure based evolution of a novel series of positive modulators of the AMPA receptor.

Craig Jamieson1, John K F Maclean, Christopher I Brown, Robert A Campbell, Kevin J Gillen, Jonathan Gillespie, Bert Kazemier, Michael Kiczun, Yvonne Lamont, Amanda J Lyons, Elizabeth M Moir, John A Morrow, John Pantling, Zoran Rankovic, Lynn Smith.   

Abstract

Starting from compound 1, we utilized biostructural data to successfully evolve an existing series into a new chemotype with a promising overall profile, exemplified by 19. Copyright Â
© 2010 Elsevier Ltd. All rights reserved.

Mesh：

Substances：

Year:  2010        PMID： 21190850     DOI： 10.1016/j.bmcl.2010.11.098

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN： 0960-894X            Impact factor:   2.823


  5 in total

1.  Rational Design of a Novel AMPA Receptor Modulator through a Hybridization Approach.

Authors:  Nicola Caldwell; Jonathan E Harms; Kathryn M Partin; Craig Jamieson
Journal:  ACS Med Chem Lett       Date:  2015-02-11       Impact factor: 4.345

2.  Functional analysis of a novel positive allosteric modulator of AMPA receptors derived from a structure-based drug design strategy.

Authors:  Jonathan E Harms; Morris Benveniste; John K F Maclean; Kathryn M Partin; Craig Jamieson
Journal:  Neuropharmacology       Date:  2012-06-23       Impact factor: 5.250

3.  Structural and functional analysis of two new positive allosteric modulators of GluA2 desensitization and deactivation.

Authors:  David E Timm; Morris Benveniste; Autumn M Weeks; Eric S Nisenbaum; Kathryn M Partin
Journal:  Mol Pharmacol       Date:  2011-05-04       Impact factor: 4.436

Review 4.  AMPA receptor potentiators: from drug design to cognitive enhancement.

Authors:  Kathryn M Partin
Journal:  Curr Opin Pharmacol       Date:  2014-11-27       Impact factor: 5.547

5.  Functional insight into development of positive allosteric modulators of AMPA receptors.

Authors:  Autumn M Weeks; Jonathan E Harms; Kathryn M Partin; Morris Benveniste
Journal:  Neuropharmacology       Date:  2014-05-27       Impact factor: 5.250
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.